imatinib mesylate has been researched along with Chromosomal Breakage in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fabarius, A; Haaß, W; Haferlach, C; Hehlmann, R; Hofmann, WK; Kleiner, H; Müller, MC; Schlegelberger, B; Seifarth, W; Weiß, C | 1 |
| Broome, HE; Curtin, PT; Dell'Aquila, ML; Rashidi, HH; Thorson, JA; Wang, HY | 1 |
| Bui-Thi, MH; Callet-Bauchu, E; Cayuela, JM; Chabane, K; Espinouse, D; Hayette, S; Magaud, JP; Nicolini, F; Ollagnier, C; Raffoux, E; Rousselot, P; Tigaud, I | 1 |
| Berman, E; Bhalla, K; Copelan, EA; Devetten, MP; Emanuel, PD; Erba, HP; Greenberg, PL; Moore, JO; O'Brien, S; Przepiorka, D; Radich, JP; Schilder, RJ; Shami, P; Smith, BD; Snyder, DS; Soiffer, RJ; Tallman, MS; Talpaz, M; Wetzler, M | 1 |
| Adám, E; Andrikovics, H; Barta, A; Bors, A; Kajtár, B; Kozma, A; Nahajevszky, S; Poros, A; Szilvási, A; Tordai, A | 1 |
| Alimena, G; Breccia, M; Cannella, L; Diverio, D; Mecarocci, S; Nanni, M; Natalino, F; Stefanizzi, C; Streponi, P | 1 |
6 other study(ies) available for imatinib mesylate and Chromosomal Breakage
| Article | Year |
|---|---|
Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Cell Line, Tumor; Chromosome Aberrations; Chromosome Breakage; Clonal Evolution; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Proteolysis; Separase; Young Adult | 2015 |
t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 4; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Karyotype; Karyotyping; Leukemia, Biphenotypic, Acute; Middle Aged; Phenotype; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2011 |
Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Base Sequence; Benzamides; Chromosome Breakage; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Sequence Data; Piperazines; Pyrimidines | 2005 |
Chronic myelogenous leukemia.
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Cytogenetic Analysis; Disease Progression; Drug Interactions; Gene Fusion; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferons; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recombinant Fusion Proteins; Remission Induction; Secondary Prevention; Translocation, Genetic; Transplantation, Homologous | 2005 |
First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Breakage; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2007 |
Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib.
Topics: Adult; Benzamides; Chromosome Breakage; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Piperazines; Pyrimidines; Thrombocytosis; Treatment Outcome | 2008 |